Penno, Giuseppe
,
Solini, Anna
Orsi, Emanuela
Bonora, Enzo
Fondelli, Cecilia
Trevisan, Roberto
Vedovato, Monica
Cavalot, Franco
Lamacchia, Olga
Scardapane, Marco
Nicolucci, Antonio
Pugliese, Giuseppe http://orcid.org/0000-0003-1574-0397
Funding for this research was provided by:
Research Foundation of the Italian Diabetes Society (Diabete Ricerca) (NA)
Boehringer Ingelheim (NA)
Chiesi Farmaceutici (NA)
Sigma-Tau Pharmaceuticals (NA)
Eli Lilly and Company (NA)
Takeda Pharmaceutical Company (NA)
Diabetes, Endocrinology and Metabolism Foundation (NA)
Article History
Received: 25 January 2018
Accepted: 12 June 2018
First Online: 21 July 2018
Duality of interest
: GPe has received: consulting fees from AstraZeneca, Boehringer Ingelheim and Eli Lilly; and lecture fees from AstraZeneca, Boehringer Ingelheim, Eli Lilly and MSD. AS has received: consulting fees from AstraZeneca, Boehringer Ingelheim and Eli Lilly; lecture fees from AstraZeneca, Boehringer Ingelheim and Eli Lilly; and grant support from AstraZeneca. EO has received consulting fees from Boehringer Ingelheim, Eli Lilly, Novo Nordisk and Sanofi Aventis; and lecture fees from Abbot, AstraZeneca, Eli Lilly, Lifescan, Sanofi Aventis and Takeda. EB has received: consulting fees from AstraZeneca, Boehringer Ingelheim and Eli Lilly; lecture fees from Bristol-Myers Squibb, Eli Lilly, Janssen, MSD, Novo Nordisk, Roche, Sanofi Aventis and Takeda; and grant support from AstraZeneca, Novo Nordisk, Roche and Takeda. RT has received: consulting fees from Boehringer Ingelheim and Sanofi Aventis; lecture fees from AstraZeneca, Boehringer Ingelheim, Eli Lilly, Janssen, Medtronic, Novartis, Novo Nordisk and Sanofi Aventis; and grant support from AstraZeneca, Boehringer Ingelheim, Eli Lilly, Janssen, Novo Nordisk and Sanofi Aventis. FC has received lecture fees from AstraZeneca, Sanofi Aventis and Takeda. OL has received: consulting fees from AstraZeneca and Boehringer Ingelheim; lecture fees from AstraZeneca, Eli Lilly, MSD, Sigma-Tau, Sanofi Aventis and Takeda; and grant support from AstraZeneca. AN has received consulting fees from Eli Lilly and Novo Nordisk; lecture fees from Eli Lilly and Novo Nordisk; and grant support from Artsana, AstraZeneca, Eli Lilly, Novo Nordisk and Sanofi Aventis. GPu has received: consulting fees from AstraZeneca, Boehringer Ingelheim, Eli Lilly and Shire; and lecture fees from AstraZeneca, Boehringer Ingelheim, Eli Lilly, MSD, Mylan, Sigma-Tau and Takeda. All other authors declare that there is no duality of interest associated with their contribution to this manuscript.